



Streamlined Reversed-Phase Method Development using a Combined Column Screening and Software Modelling Approach

Alan P McKeown
amckeown@ace-hplc.com

Business Development Director

Advanced Chromatography Technologies Ltd





Overview

- ◆ **Method Development and Strategies.**
- ◆ **Maximising Selectivity: a Systematic Screening Approach.**
- ◆ **Use of ChromSword software for method optimisation.**



Reversed-Phase Method Development

- ◆ Method development is typically an **iterative process** which can take time depending upon separation and sample complexity.
- ◆ Several approaches are commonly used for method development:
 - ◆ Trial and error
 - ◆ Stepwise, one factor at a time (OFAT)
 - ◆ Quality by Design (QbD)
 - ◆ Systematic Screening
- ◆ Logical, **well structured** method development processes can help to **efficiently develop** separations and **robust** LC methods.



Systematic Screening

- ◆ A **systematic screening approach** applies a common screening protocol to explore specific chromatographic parameters which maximise selectivity.
- ◆ Can be **semi-automated** with a suitable LC instrument eg **VWR-Hitachi ChroMaster LC instrument**.
- ◆ The screening process may identify a **combination** of these parameters that provide a separation.



Resolution, Selectivity, Efficiency & Retention


Particle size, column length, dispersion etc

Phase design, eluent etc

Efficiency Selectivity Retention

$$R_s = \frac{\sqrt{N}}{4} \cdot \frac{\alpha-1}{\alpha} \cdot \frac{k}{1+k}$$

Selectivity (α) is the key to resolution and efficiency (N) boosts performance






Which Factors¹ Affect Selectivity?

- ◆ Strongly influenced by physicochemical properties of the analyte, stationary phase, eluent etc
- ◆ From a practical perspective:

Isocratic Separations

MOST
Influence

- ◆ Column stationary phase type
- ◆ pH (ionisable analytes only)
- ◆ Organic modifier type
- ◆ % Organic modifier
- ◆ Buffer selection
- ◆ Column temperature
- ◆ Buffer concentration



LEAST
Influence

Gradient Separations

All parameters for isocratic **PLUS**

Gradient steepness

$k^*(t_G, F, V_m, \Delta\Phi, M)$

$$k^* = \frac{t_G F}{\Delta\Phi V_m M}$$

Dwell volume


Column dimensions




Scientific Led Stationary Phase Design: Aromatic Phases

Electron Donating Groups
eg NH_2 , NR_2 , alkyl, OCH_3 ,
 OR , CH_3 , Ar etc

e.g.




Electron Rich Ring




Activity: π -donor (π -base)

Electron Withdrawing Groups
eg NO_2 , halides, NR_3^+ , CO_2H ,
 CN , CO_2R , SO_3H , COH etc

e.g.



Electron Deficient Ring



Activity: π -acceptor (π -acid)

How do we exploit these properties for new stationary phases?



C18+Phenyl = ACE® C18-AR

Both phases have multiple mechanisms of interaction, low bleed
and are 100% wettable: i.e. maximize selectivity

C18+PFP = ACE® C18-PFP



Stationary Phase Selectivity: Regioisomers

4 peaks?

ACE Excel 2 C18




Isocratic analysis

1:1 v/v MeOH:H₂O
0.21 ml/min
40 °C
210 nm

P = 150 bar

5 peaks?


ACE Excel 2 C18-AR



P = 146 bar

7 peaks

ACE Excel 2 C18-PFP



Hydrophobic + π-π + dipole
+ shape / position selectivity

P = 147 bar


Stationary Phase Selectivity Is Powerful




Scientific Led Stationary Phase Design: Other Phases

ACE C18-Amide

C18 carbon chain tail



ACE CN-ES



Multiple mechanisms of interaction, low bleed and are 100% wettable: i.e. maximize selectivity


**ACE®**

HPLC / UHPLC Columns

10


Catechols and Resorcinols Separations

ACE C18-Amide



- Phenolic selectivity
- Enhanced polar retention

ACE C18





Stationary Phase Key Mechanisms of Interactions

- ◆ Tanaka¹ characterisation can help understand mechanisms and weightings with different column chemistries

Bonded Phase	Separation Mechanism and Relative Strength ¹				
	Hydrophobic Binding	π-π Interaction	Dipole-Dipole	Hydrogen Bonding	Shape Selectivity
ACE C18	****	-	-	*	**
ACE C18-AR	****	*** (donor)	*	**	***
ACE C18-PFP	****	*** (acceptor)	****	***	****
ACE SuperC18	****	-	-	-	**
ACE C18-Amide	****	-	**	****	**/***
ACE CN-ES	***	*	***	**	*

Approximate value – determined by semi-quantitative mechanism weightings and/or by reference to other ACE phases using >100 characterising analytes.



Stationary Phase Key Mechanisms of Interactions

- ◆ Specifically designed phases to maximize selectivity

Bonded Phase	Separation Mechanism and Relative Strength ¹				
	Hydrophobic Binding	π-π Interaction	Dipole-Dipole	Hydrogen Bonding	Shape Selectivity
ACE C18	****	-	-	*	**
ACE C18-AR	****	*** (donor)	*	**	***
ACE C18-PFP	****	*** (acceptor)	****	***	****
ACE SuperC18	****	-	-	-	**
ACE C18-Amide	****	-	**	****	**/***
ACE CN-ES	***	*	***	**	*

Approximate value – determined by semi-quantitative mechanism weightings and/or by reference to other ACE phases using >100 characterising analytes.


- ◆ Multiple mechanisms of interaction: ideal for method development



Selectivity, Method Development: 6 Column Switcher

- ◆ 6 stationary phases, 1 solvent, low pH

MeCN



**6 Column Method Development Platform
Based Upon The Power of Phase Chemistry / Selectivity**


**ACE®**

HPLC / UHPLC Columns

14

Explore Selectivity for Method Development


- ◆ 45 analytes, 6 stationary phases, 2 solvents, 1 low pH



**6 Column, 2 Solvent Method Development Platform
Based Upon The Power of Selectivity**



Total Selectivity, Method Development: Screening Platform





General LC Method Development Approach

Overview of method development steps

- ◆ **Step 1: Scouting runs with general starting conditions**
- ◆ Step 2: Optimize for peak shape, run time etc
- ◆ Step 3: Validate according to local guidance
- ◆ Step 4: Transfer / Implement



General Method Development Initial Conditions

- ♦ Perform a **broad scouting gradient** run on the samples at **acidic eluent pH**
- ♦ How do you calculate your starting conditions?

For a 100 x 3mm column:

t_G	= 5 minutes
F	= 1.2 mL/min
$\Delta\phi$	= 0.95
V_m	= 0.459 mL
M	= 5



$$k^* = \frac{t_G F}{\Delta\phi V_m M} = \sim 3$$

- ♦ Ideally retention (or k^* in gradient elution) should be **>2** and **<20** for initial method development



Paracetamol Plus Some Impurities For Method Development

1. Acetaminophen	API (a.k.a. Paracetamol)
2. 4-aminophenol	Synthesis/degradation product
3. Hydroquinone	Deg product of 4-aminophenol
4. 2-aminophenol	Included as would be a synthesis impurity of (8) if not fully removed
5. 2-acetamidophenol	Specified in USP
6. Phenol	Included as extra compound
7. 4-nitrophenol	Ph. Eur. related substance
8. 2-nitrophenol	Synthesis impurity of 4-amino phenol (39% yield, normally removed by steam distillation)
9. 4-chloroacetanilide	Eu. Ph. related substance
10. 4-chlorophenol	Potential low-level impurity



General scouting conditions:

100 x 3.0 mm columns

A: 20 mM Ammonium acetate pH 6.0

B: 20 mM Ammonium acetate pH 6.0 in MeOH or MeCN:H₂O (9:1 v/v)


Gradient: 5 to 95% B in 10 mins

Temp: 40 °C, 2 µL injection, Flow rate: 1.2 mL/min

Sample: Acetaminophen with rel subs at 0.5% w/w



Total Selectivity, Method Development: Screening Platform




**ACE®**

HPLC / UHPLC Columns

MeCN

20


Total Selectivity, Method Development: Screening Platform



peaks resolved


ACE Excel 2 C18 100 x 3.0 mm

8/10

Acetaminophen
and related analytes


ACE Excel 2 C18-AR 100 x 3.0 mm

10/10




ACE Excel 2 C18-PFP 100 x 3.0 mm

10/10




ACE Excel 2 SuperC18 100 x 3.0 mm

10/10



ACE Excel 2 C18-Amide 100 x 3.0 mm

8/10



ACE Excel 2 CN-ES 100 x 3.0 mm

10/10


Six options
direct from
the screening
data.

No further
development
required.


**ACE®**

HPLC / UHPLC Columns

The Complete Method Development Screening Solution




- ◆ The ACE Reversed-Phase Method Development Flow Chart provides a simple to follow tool for efficient and streamlined method development using the ACE novel phases.
- ◆ Available as a free A2 Poster.





Optimising the separation



- ◆ The screening data is used to select a **column/organic modifier combination** for method optimisation.
- ◆ Method optimisation may require investigation of **other parameters:**
 - Gradient time and %B range
 - Temperature
 - pH
- ◆ **Method development software** can be used to facilitate the optimisation.



ChromSword 2




- ◆ **Method development software can be used to model, predict and optimise separations in:**
 - Reversed Phase Chromatography
 - % Organic
 - Gradient time
 - pH
 - Temperature
 - Also Compatible with Normal Phase and Ion Exchange Chromatography



Method Optimisation with ChromSword 2



- ♦ Input from as few as **two initial runs** into the software to build a **tG retention model**.
- ♦ Additional runs can also be included to **improve and validate** the **accuracy** of the model.





Method Optimisation with ChromSword 2



- ♦ Input from as few as two initial runs entered into the software to build a retention model.
- ♦ Additional runs can also be included to improve and validate the accuracy of the model.
- ♦ Can now **simulate the separation** and adjust manually.






Method Optimisation with ChromSword 2

- ◆ Input from as few as two initial runs entered into the software to build a retention model.
- ◆ Additional runs can also be included to improve and validate the accuracy of the model.
- ◆ Can now simulate the separation and adjust manually.
- ◆ ChromSword can also **automatically** optimise the separation.



6 Column Screen of Triple API sample + Impurities (17 peaks)



- ♦ Methanol provides **better retention and selectivity** for the more hydrophilic analytes.
- ♦ The screening approach provides **multiple options** to pursue for obtaining a full separation.
- ♦ The ACE C18, C18-AR and C18-Amide all resolve 11 of the 14 impurity peaks.

1. 2-Aminophenol, 2. Hydroquinone, 3. Theobromine, 4. Paracetamol,
5. Theophylline, 6. Paraxanthine, 7. 4-Hydroxybenzoic acid,
8. Caffeine, 9. 2-Acetamidophenol, 10. 2-Hydroxybenzoic acid,
11. Phenol, 12. Aspirin, 13. 4-Nitrophenol, 14. 4-Chloroacetanilide,
15. 2-Nitrophenol, 16. Acetylsalicylsalicylic acid, 17. Salsalate



ACE®







HPLC / UHPLC Columns

MeCN

28

6 Column Screen of Triple API sample + Impurities (17 peaks)

○ coelution



- ◆ Columns: 6 x ACE Excel 2, 100 x 3.0 mm
- ◆ System: ChromasterUltra Rs
- ◆ A: 10 mM ammonium formate pH 3.0
- ◆ B1: 10 mM ammonium formate pH 3.0 in MeCN:H₂O 9:1 v/v
- ◆ B2: 10 mM ammonium formate pH 3.0 in MeOH:H₂O 9:1 v/v
- ◆ Gradient: 5-95% B in 5 minutes
- ◆ Temp: 40 °C
- ◆ Flow rate: 1.2 mL/min
- ◆ Detection: UV, 270 nm
- ◆ Sample:
 - Aspirin: 5 mg/mL
 - Paracetamol: 3.3 mg/mL
 - Caffeine: 0.75 mg/mL
 - Impurities spiked at 0.1% (wrt aspirin)

- 1. 2-Aminophenol, 2. Hydroquinone, 3. Theobromine, 4. Paracetamol, 5. Theophylline, 6. Paraxanthine, 7. 4-Hydroxybenzoic acid, 8. Caffeine, 9. 2-Acetamidophenol, 10. 2-Hydroxybenzoic acid, 11. Phenol, 12. Aspirin, 13. 4-Nitrophenol, 14. 4-Chloroacetanilide, 15. 2-Nitrophenol, 16. Acetylsalicylsalicylic acid, 17. Salsalate




Optimising the separation with ChromSword 2

- ◆ **Selected column: ACE Excel 2 C18-Amide 100 x 3.0 mm**
- ◆ A: 10 mM ammonium formate pH 3.0
- ◆ B: 10 mM ammonium formate pH 3.0 in MeOH:H₂O 9:1 (v/v)
- ◆ The 5 minute screening gradient run was input into ChromSword.
- ◆ 10 and 15 minute gradients were also run and input to generate the tG model.
- ◆ The separation was optimised and the optimum linear gradient was predicted.
- ◆ (Further optimisation was achieved: prediction of multi-step gradients).



Optimising the separation with ChromSword 2



- Optimum predicted linear gradient





Optimising the separation with ChromSword 2


◆ Optimum predicted linear gradient





Optimising the Separation with ChromSword 2

- ◆ Step Gradient: Target run time 10 minutes
- ◆ A 5 node gradient is predicted to give the optimum separation







ACE®

HPLC / UHPLC Columns

Optimising the separation with ChromSword 2

◆ Step Gradients: Target run time 10 minutes




Compound	Predicted t_R	Experimental t_R	% error
2-aminophenol	0.71	0.612	13.8
hydroquinone	1.05	1.015	3.3
theobromine	1.18	1.135	3.8
paracetamol	1.42	1.368	3.7
paraxanthine	1.62	1.543	4.8
theophylline	1.83	1.738	5.0
2-acetamidophenol	2.20	2.128	3.3
caffeine	2.40	2.358	1.7
4-hydroxybenzoic acid	2.66	2.665	-0.2
phenol	2.82	2.820	0.0
aspirin	3.07	3.062	0.3
2-hydroxybenzoic acid	3.47	3.463	0.2
4-nitrophenol	5.12	5.122	0.0
4-chloroacetanilide	5.97	5.975	-0.1
2-nitrophenol	4.30	4.289	0.3
ASSA	7.71	7.699	0.1
Salsalate	11.18	11.338	-1.4

Gradient Profile	
t	%B
0.0	12.0
1.7	18.0
1.9	31.0
4.4	31.0
5.1	44.0



Optimising the separation with ChromSword 2


- ◆ Increase weighting (i.e. importance) for the separation of peaks 4 and 5.
- ◆ A 4 node gradient is predicted to give the optimum separation.






Optimising the separation with ChromSword 2

- ◆ Profile manual editing also possible to ‘tweak’ if necessary
- ◆ The final gradient step was manually edited to reduce run time.



t	%B
0.0	10.0
1.6	10.0
2.2	34.0
8.3	53.0




t	%B
0.0	10.0
1.6	10.0
2.2	34.0
4.0	40.0
5.0	90.0




Optimising the separation with ChromSword 2

◆ Final separation.

Predicted



Experimental



Compound	Predicted t_R	Experimental t_R	% error
2-aminophenol	0.71	0.633	10.8
hydroquinone	1.14	1.098	3.7
theobromine	1.47	1.395	5.1
paracetamol	1.70	1.633	3.9
paraxanthine	2.14	2.064	3.6
theophylline	2.37	2.357	0.5
2-acetamidophenol	2.54	2.554	-0.6
caffeine	2.69	2.747	-2.1
4-hydroxybenzoic acid	2.90	2.933	-1.1
phenol	3.02	3.039	-0.6
aspirin	3.21	3.26	-1.6
2-hydroxybenzoic acid	3.54	3.559	-0.5
2-nitrophenol	4.16	4.189	-0.7
4-nitrophenol	4.66	4.697	-0.8
4-chloroacetanilide	5.01	5.027	-0.3
ASSA	5.17	5.21	-0.8
Salsalate	5.42	5.452	-0.6



Summary and Conclusions

- ◆ **Systematic screening is a logical and productive approach to LC method development.**
- ◆ **Stationary phase and organic modifier** are two of the most **powerful parameters** for exploring the **selectivity** of a separation.
- ◆ The **6-column, 2-solvent** platform described is designed to quickly identify the most promising **column/organic solvent combination** for a separation.
- ◆ **ChromSword 2** provides an efficient tool for method optimisation once the column/mobile phase have been selected.



ACE® HPLC / UHPLC Columns

38

ACE-CS2.0 Method Development Solution



ACE®
ChromSword Method Development Kits

Intelligent Solutions for Method Development



Thank You For Your Attention

www.mac-mod.com

info@mac-mod.com